Employingthis assay platform in a chemical genomics screen of 1800 annotated compoundsenabled identification of small molecule perturbagens capable of enhancing cytotoxicCD8+ T-cell activity in an antigen-dependent manner.Specifically, cyclin-dependent kinase (CDK) and bromodomain (BRD) protein inhibitorswere shown to significantly augment anti-tumor T-cell function by increasingcytolytic granule and type II interferon secretion in T-cells in addition toupregulating major histocompatibility complex (MHC) expression and antigenpresentation in tumor cells. The gene discussed is HLA-C; the disease is neoplasm.